Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis
Key facts
- Who runs it
- Singapore National Eye Centre
- Where
- Singapore1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 25 people enrolled
- Started
- Oct 2016
- Ended
- 30 Nov 2024
- Type of study
- Interventional
- Treatments tested
- 2% guttae ganciclovir
- Record updated
- 18 May 2025
Who can take part
- Age
- 21 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Age between 21 and above
- Patients who are diagnosed with anterior uveitis or endotheliitis with a positive aqueous real time PCR (RT-PCR) and/or positive tetraplex PCR for Cytomegalovirus (CMV)
- Patients with relapses and recurrent anterior segment disease that is PCR positive for CMV in aqueous
- Have not been on any form of (topical, local or systemic) ganciclovir therapy for the past 1 month
- Consent to undergo anterior chamber tap and give aqueous and tear samples for the study
- Able to undergo relevant tests (e.g. laser flare cell photometry)
- Able to come for subsequent follow-up visits
- Ability to provide informed consent
Who cannot take part
- Patients who have been on any form of (topical, local or systemic) ganciclovir therapy for the past1 month
- Patients who will require systemic or intra-vitreal ganciclovir therapy
- Other causes of hypertensive anterior uveitis / endotheliitis such as HSV, VZV infection
- Patients who are allergic to ganciclovir
- Positive for HIV, Hep B and Hep C
- CMV anterior uveitis with associated retinitis
- Immunocompromised patients
- Not keen on participating in the study
- Patients who are incapable, either by law or mental state, of giving consents in their own right
- Patients who are either unable or unwilling to keep scheduled appointments and adhere to the other aspects of the protocol
- Patients who are pregnant or breastfeeding
- Any other specified reason as determined by the clinical investigator
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
25 patients who are diagnosed with Cytomegalovirus (CMV) anterior segment infection, either uveitis or endotheliitis, will be started on 2% guttae ganciclovir, 1 drop 5 times a day for 6 weeks.
Read full original descriptionShow less
Following 6 weeks of continuous application of 2% guttae ganciclovir, patient will be reviewed at the clinic within 3 hours following the last application of topical ganciclovir and clinical features will be documented for activity assessment. An aqueous sample 0.2ml is drawn. 0.1ml will be sent for RT-PCR for CMV viral load and another 0.1ml will be sent for ganciclovir drug level by HPLC method.
The group in the trial
- 2% guttae GanciclovirTreatment being tested
2% guttae Ganciclovir 5 times a day for 6 weeks
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Intra-cameral Penetration and Efficacy of Ganciclovir Following Topical Administration of 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis
- Publications
- Aqueous humour concentration of topically applied 2.0% ganciclovir eye drops in eyes with cytomegalovirus anterior uveitis and endotheliitis.Clinical & experimental ophthalmology, 2025
- Record updated
- 18 May 2025